Swedish Orphan Biovitrum AB: Zynlonta (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta

Related Keywords

Norway ,Iceland ,United States ,New Jersey ,Stockholm ,Sweden ,United Kingdom ,Liechtenstein ,Switzerland ,London ,City Of ,America ,Swedish ,Lausanne Biop ,Anders Ullman ,Prnewswire Sobi ,Linkedin ,Company On Twitter ,European Commission ,Drug Administration ,Sobi Investor Relations Team ,Youtube ,Committee For Orphan Medicinal Products ,European Union ,Head Of Research Development ,Medicinal Products ,Human Use ,European Medicines Agency ,Medical Affairs ,Chief Medical Officer ,Ameet Mallik ,Chief Executive Officer ,Orphan Medicinal Products ,San Francisco Bay Area ,Cancer Research United Kingdom ,North America ,Middle East ,Sobi Media ,Orphan ,Iovitrum ,Zynlonta ,Loncastuximab ,Esirine ,Approved ,Treatment ,Relapsed ,Refractory ,Diffuse ,Barge ,Fell ,Lymphoma ,